# Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

> **NCT04758975** · PHASE2 · RECRUITING · sponsor: **Paolo Ghia** · enrollment: 55 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Rituximab
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT04758975
- **Lead sponsor:** Paolo Ghia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-19
- **Primary completion:** 2024-12-31
- **Final completion:** 2027-12-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04758975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04758975, "Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04758975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*